Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
ORTHO-NOVUM 1/35-28 is an oral contraceptive tablet containing norethindrone and ethinyl estradiol in a 28-day cycle formulation. It prevents pregnancy through hormonal suppression of ovulation and is a foundational product in the combined oral contraceptive class. This small molecule product has been a market standard since approval in 1977.
Mature franchise approaching LOE with moderate competitive pressure (30%), signaling likely downsizing of dedicated brand infrastructure and transition to maintenance-mode operations.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORTHO-NOVUM 1/35-28 offers limited growth trajectory; roles are primarily defensive, focused on market share preservation and managed care optimization in a contracting franchise. Career progression is constrained—expect focus on operational efficiency and potential consolidation with other legacy contraceptive products rather than expansion initiatives.
Worked on ORTHO-NOVUM 1/35-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.